Results 31 to 40 of about 24,049 (149)
FGFR2 Fusions or Rearrangements in Young Intrahepatic and Perihilar Cholangiocarcinoma Patients: Key Genetic Insights From a Pan‐Asian Study
Hepatology Research, EarlyView.FGFR2 Alterations in Young Adults with cholangiocarcinoma was common. Intrahepatic cholangiocarcinoma (ICC) is a rare liver cancer, typically seen in older adults. This study focused on younger patients across Asia, examining changes in the FGFR2 gene that may drive cancer growth.Yuta Maruki, Yasushi Yatabe, Chiharu Mizoguchi, Kathleen Yasmin de Almeida, Aumkhae Sookprasert, Charuwan Akewanlop, Ming‐Huang Chen, Ekaphop Sirachainan, Dao Van Tu, Rozita Abdul Malik, Chaiyut Charoentum, Hwoei Fen Soo Hoo, Suhana Yusak, Tsung‐Hao Liu, Rangasamy Ramachandran, Patrapim Sunpaweravong, Pei Jye Voon, Najihah Abu Bakar, Junki Mizusawa, Hitomi Sumiyoshi Okuma, Kenichi Nakamura, Chigusa Morizane, Takuji Okusaka +22 morewiley +1 more sourceEfficacy and Safety of Hypofractionated Radiation Therapy Combined With Immunotherapy for Hepatocellular Carcinoma With Vp4 Portal Vein Tumor Thrombosis
Hepatology Research, EarlyView.ABSTRACT Background
Hepatocellular carcinoma (HCC) with Vp4 portal vein tumor thrombosis (PVTT) has an extremely poor prognosis, and evidence for effective systemic therapy is limited. Preclinical studies suggest that hypofractionated radiation therapy (HFRT) may enhance immune checkpoint inhibitor (ICI) efficacy through immunogenic cell death and ...Masahiko Tameda, Hideaki Tanaka, Yutaka Toyomasu, Mizuki Kawachi, Hirono Owa, Mone Tsukimoto, Yasuyuki Tamai, Naoto Fujiwara, Ryuta Shigefuku, Suguru Ogura, Yoshihito Nomoto, Hayato Nakagawa +11 morewiley +1 more sourceCurrent practice of pathologic response assessment following chemoimmunotherapy for non‐small cell lung cancer (NSCLC) in Germany: first real‐world data from the multicentre Re‐GraDE study
Histopathology, EarlyView.Re‐GraDE, a multicentre German study including 133 cases, highlights variability in regression grading, macroscopic tumour workup, and use of Junker/IASLC systems after neoadjuvant immuno‐chemotherapy in NSCLC. Results from Junker and IASLC systems are comparable. A weak correlation was found between pretreatment PD‐L1 status and residual viable tumour Felix Elsner, Christiane Kümpers, German Ott, Julia Döring, Katharina Schildknecht, Annette Fisseler‐Eckhoff, Maximilian von Laffert, Lea Baier, Luca Giulini, Dietmar Kraus, Jozef Zustin, Florian Weber, Tamas Szöke, Merle Kögel, Annette Arndt, Verena Büchele, Hanibal Bohnenberger, Florian Fuchs, Christian Matek, Konrad Steinestel, on behalf of the Pulmonary Pathology Working Group of the German Society of Pathology +20 morewiley +1 more sourceCutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies
International Journal of Dermatology, EarlyView.ABSTRACT Introduction
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%David O'Reilly, Gregg Murray, Orla M Fitzpatrick, Hebatalla Ismail, Gavin P Dowling, Gargi Roy, David Synnott, Maggie O'Connor, Bryan T Hennessy, Oscar Breathnach, Liam Grogan, Megan Greally, Adrian Murphy, Patrick G Morris, Karen Eustace, Muireann Roche, Stephen Madden, Jarushka Naidoo +17 morewiley +1 more sourceAdvances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians
CA: A Cancer Journal for Clinicians, EarlyView.Abstract
Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer‐related death worldwide. Contemporary advances in systemic and locoregional therapies have led to changes in peer‐reviewed guidelines regarding systemic therapy as well as the possibility of downstaging disease that may enable some patients Dimitrios Moris, Alessandro Martinino, Sarah Schiltz, Peter J. Allen, Andrew Barbas, Debra Sudan, Lindsay King, Carl Berg, Charles Kim, Mustafa Bashir, Manisha Palta, Michael A. Morse, Michael E. Lidsky +12 morewiley +1 more sourceUrothelial carcinoma: Perioperative considerations from top to bottom
CA: A Cancer Journal for Clinicians, EarlyView.Abstract
Urothelial carcinoma is an aggressive entity that is associated with significant morbidity, but there have been major advances in both our understanding of and treatment options for patients with this disease. In this review, the authors focus on novel therapeutic and diagnostic approaches in the perioperative setting, with an emphasis on ...Wesley Yip, Salvador Jaime‐Casas, Anjaney Kothari, Mary Sullivan, Leslie K. Ballas, Domenique Escobar, Anne K. Schuckman, Jonathan E. Rosenberg, Jonathan A. Coleman +8 morewiley +1 more sourceSetting the Benchmark: Patterns of Care and Outcomes for Early‐stage Non‐small Cell Lung Cancer in Queensland, Australia, 2011–2017
Asia-Pacific Journal of Clinical Oncology, Volume 21, Issue 6, Page 597-606, December 2025.This study uses a population‐based cohort of patients diagnosed with early‐stage non‐small cell lung cancer in Queensland between 2011 and 2017 to establish baseline data on patterns of care. Our findings are intended to lay the groundwork to better understand the benefits of immunotherapy which was subsequently introduced.Bryan A. Chan, Danny R. Youlden, Tracey Guan, Margot Lehman, Morgan Windsor, Alison Bolton, Nathan Dunn, Danica Cossio, Shoni Philpot, Jasotha Sanmugarajah +9 morewiley +1 more sourceAtezolizumab Plus Bevacizumab for TACE‐Unsuitable Intermediate‐Stage HCC Beyond Up‐To‐7 Criteria: Final Analysis of REPLACEMENT
Liver International, Volume 45, Issue 12, December 2025.ABSTRACT Background and Aims
The phase II REPLACEMENT study showed promising clinical benefit from atezolizumab plus bevacizumab in transcatheter arterial chemoembolization (TACE)–naïve patients with intermediate‐stage hepatocellular carcinoma (HCC) beyond up‐to‐7 criteria, meeting its primary endpoint of progression‐free survival (PFS).Kazuomi Ueshima, Kaoru Tsuchiya, Tatsuya Yamashita, Shigeo Shimose, Kazushi Numata, Yuzo Kodama, Shinji Itoh, Yasuhito Tanaka, Hidekatsu Kuroda, Kazuyoshi Ohkawa, Teiji Kuzuya, Masafumi Ikeda, Youhei Kooka, Hiroshi Aikata, Atsushi Hiraoka, Michihisa Moriguchi, Ryosuke Tateishi, Sadahisa Ogasawara, Kouji Yamamoto, Masatoshi Kudo +19 morewiley +1 more sourceNegative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
International Journal of Cancer, Volume 157, Issue 10, Page 2092-2102, 15 November 2025.What's new?
In recent years, the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations has generated increasing interest. This real‐world analysis evaluated the impact of concomitant medications on survival outcomes in patients with advanced biliary tract cancer treated with cisplatin ...Federica Lo Prinzi, Francesca Salani, Silvia Camera, Mario Domenico Rizzato, Anna Saborowski, Lorenzo Antonuzzo, Federico Rossari, Tomoyuki Satake, Frederik Peeters, Tiziana Pressiani, Jessica Lucchetti, Jin Won Kim, Oluseyi Abidoye, Ilario Giovanni Rapposelli, Chiara Gallio, Stefano Tamberi, Fabian Finkelmeier, Guido Giordano, Pircher Chiara, Hong Jae Chon, Chiara Braconi, Aitzaz Qaisar, Alessandro Pastorino, Florian Castet, Emiliano Tamburini, Changhoon Yoo, Alessandro Parisi, Anna Diana, Mario Scartozzi, Gerald W. Prager, Antonio Avallone, Marta Schirripa, Il Hwan Kim, Lukas Perkhofer, Ester Oneda, Monica Verrico, Nuno Couto, Jorge Adeva, Stephen L. Chan, Gian Paolo Spinelli, Nicola Personeni, Ingrid Garajova, Maria Grazia Rodriquenz, Silvana Leo, Cecilia Melo Alvim, Ricardo Roque, Mariam Grazia Polito, Emanuela Di Giacomo, Giovanni Farinea, Linda Bartalini, Giada Grelli, Antonio De Rosa, Daniele Lavacchi, Masafumi Ikeda, Jeroen Dekervel, Monica Niger, Rita Balsano, Giuseppe Tonini, Minsu Kang, Giulia Tesini, Alessandra Boccaccino, Vera Himmelsbach, Matteo Landriscina, Selma Ahcene Djaballah, Tanios Bekaii‐Saab, Lorenzo Fornaro, Gianluca Masi, Arndt Vogel, Sara Lonardi, Margherita Rimini, Lorenza Rimassa, Andrea Casadei‐Gardini +71 morewiley +1 more sourceCancer‐Associated Fibroblasts: Origin, Classification, Tumorigenicity, and Targeting for Cancer Therapy
MedComm, Volume 6, Issue 11, November 2025.This review explores the multifaceted roles of cancer‐associated fibroblasts (CAFs) in tumor biology. It examines their diverse origins, dynamic activation via signaling pathways, and spatial–temporal heterogeneity, proposing an updated classification of eight distinct CAF subtypes. The review highlights CAFs' contributions to tumor growth, metastasis, Chang Fan, Wenlong Zhu, Yuan Chen, Wanwan Zhu, Jin Ding +4 morewiley +1 more source
